XOMA logo

XOMA Corporation

XOMA

XOMA: XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

more

Show XOMA Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of XOMA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by XOMA's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $30,000 Jan 20, 2016 Issue: None
  • $60,000 Aug 24, 2015 Issue: Health Issues
  • $30,000 Aug 04, 2015 Issue: Health Issues
  • $110,000 Apr 20, 2015 Issue: Taxation/Internal Revenue Code Health Issues
  • $30,000 Jan 16, 2015 Issue: Health Issues Taxation/Internal Revenue Code
  • $50,000 Oct 20, 2014 Issue: Taxation/Internal Revenue Code Health Issues
  • $20,000 Aug 14, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $20,000 Jan 19, 2012 Issue: Defense
  • $30,000 Oct 20, 2011 Issue: Homeland Security Defense Copyright/Patent/Trademark Budget/Appropriations
  • $80,000 Jul 20, 2011 Issue: Defense Copyright/Patent/Trademark Health Issues Budget/Appropriations Homeland Security
  • $80,000 Apr 19, 2011 Issue: Health Issues Defense Copyright/Patent/Trademark Budget/Appropriations
  • $40,000 Jan 19, 2011 Issue: Health Issues Defense Budget/Appropriations
  • $60,000 Oct 20, 2010 Issue: Budget/Appropriations Health Issues Defense
  • $120,000 Oct 19, 2010 Issue: Defense Budget/Appropriations
  • $120,000 Jul 19, 2010 Issue: Financial Institutions/Investments/Securities Defense Homeland Security Health Issues Budget/Appropriations
  • $50,000 Jan 20, 2010 Issue: Defense Budget/Appropriations
  • $90,000 Oct 19, 2009 Issue: Medical/Disease Research/Clinical Labs Defense
  • $120,000 Jul 20, 2009 Issue: Defense
  • $130,000 Apr 16, 2009 Issue: Defense
  • $260,000 Jan 21, 2009 Issue: Defense Medical/Disease Research/Clinical Labs
  • $150,000 Oct 16, 2008 Issue: Medical/Disease Research/Clinical Labs Defense
  • $180,000 Oct 16, 2008 Issue: Medical/Disease Research/Clinical Labs Defense
  • $150,000 Apr 21, 2008 Issue: Science/Technology Pharmacy Taxation/Internal Revenue Code Disaster Planning/Emergencies Homeland Security
  • $120,000 Feb 12, 2008 Issue: Homeland Security Disaster Planning/Emergencies Science/Technology Taxation/Internal Revenue Code Pharmacy
  • $100,000 Feb 14, 2007 Issue: Government Issues
  • $100,000 Aug 17, 2006 Issue: Government Issues
  • $80,000 Feb 17, 2006 Issue: Government Issues
  • $20,000 Aug 15, 2005 Issue: Government Issues
U.S. Patents

New patents grants

  • Patent Title: Method of increasing the ratio of effector t cells to regulatory t cells in a tumor by administering to a subject a tgf-beta inhibitor and a pd-1 antibody Jun. 27, 2023
  • Patent Title: Compositions and methods for delaying the incidence of labor Dec. 27, 2022
  • Patent Title: Modulators Mar. 01, 2022
  • Patent Title: Method of treating cancer by administering an antibody that binds transforming growth factor beta (tgf-beta) 1, tgf-beta 2 and tgf-beta 3 Aug. 24, 2021
  • Patent Title: Antibodies that bind interleukin-2 and uses thereof Dec. 08, 2020
  • Patent Title: Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery Jul. 14, 2020
  • Patent Title: Treatment of cancer using anti-tgf-β and anti-pd-1 antibodies Jun. 16, 2020
  • Patent Title: Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof Dec. 31, 2019
  • Patent Title: Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (tgf)-β Jul. 23, 2019
  • Patent Title: Flexible manufacturing system May. 21, 2019
  • Patent Title: Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia Apr. 09, 2019
  • Patent Title: Treatment of cancer using anti-tgf-beta and pd-1 antibodies Jan. 01, 2019
  • Patent Title: Flexible manufacturing system Oct. 23, 2018
  • Patent Title: Modulators Apr. 17, 2018
  • Patent Title: Screening methods Feb. 06, 2018
  • Patent Title: Methods and materials for enhancing functional protein expression in bacteria Aug. 15, 2017
  • Patent Title: Modulators Aug. 08, 2017
  • Patent Title: Tgf-beta-specific antibodies and methods of use thereof for treatment Jul. 25, 2017
  • Patent Title: Pharmaceutical compositions comprising il-1b binding antibodies and fragments thereof Dec. 08, 2015
  • Patent Title: Methods for the treatment of il-1β related diseases Oct. 20, 2015
  • Patent Title: Antibodies specific for tgf-β and methods of treatment thereof Sep. 29, 2015
  • Patent Title: Methods for the treatment of uveitis with il-1β binding antibodies Sep. 22, 2015
  • Patent Title: Methods and materials for targeted mutagenesis Aug. 11, 2015
  • Patent Title: Modulators Jan. 06, 2015
  • Patent Title: Anti-botulism antibody coformulations Sep. 02, 2014
  • Patent Title: Methods for the treatment of gout Jan. 28, 2014
  • Patent Title: Methods for the treatment of il-1β related diseases Nov. 19, 2013
  • Patent Title: Flexible manufacturing system Nov. 19, 2013
  • Patent Title: Antibodies specific for tgf-beta and methods for treating thereof Oct. 29, 2013
  • Patent Title: Methods for the treatment of il-1β related conditions Oct. 08, 2013
  • Patent Title: Triple tag sequences and methods of use thereof Oct. 01, 2013
  • Patent Title: Triple tag sequence and methods of use thereof Oct. 01, 2013
  • Patent Title: Methods for treating il-1β related diseases by administering an anti-il-1β antibody Oct. 01, 2013
  • Patent Title: Methods and materials for increasing expression of recombinant polypeptides Jul. 30, 2013
  • Patent Title: Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries Jul. 02, 2013
  • Patent Title: Method of treating inflammatory eye disease with il-1β binding antibodies Feb. 19, 2013
  • Patent Title: Methods for improvement of beta cell function with anti-il-1β antibodies or fragments thereof Feb. 19, 2013
  • Patent Title: Antibodies to high molecular weight melanoma associated antigen Nov. 27, 2012
  • Patent Title: Methods for the treatment of il-1β related diseases Jan. 24, 2012
  • Patent Title: Methods and materials for increasing expression of recombinant polypeptides Aug. 09, 2011
  • Patent Title: Method of treating an il-1 related coronary condition Aug. 02, 2011
  • Patent Title: Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries Jul. 12, 2011
  • Patent Title: Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries Jul. 05, 2011
  • Patent Title: Il-1β binding antibodies and fragments thereof May. 17, 2011
  • Patent Title: Method of treating an il-1 related cancer Nov. 09, 2010
  • Patent Title: Method of treating an il-1 related autoimmune disease or condition Nov. 09, 2010
  • Patent Title: Methods and materials for expression of a recombinant protein Sep. 14, 2010
  • Patent Title: Methods for recombinant peptide production Jul. 06, 2010
  • Patent Title: Il-1β binding antibodies and binding fragments thereof Jun. 29, 2010
  • Patent Title: Il1-β binding antibodies and fragments thereof Jun. 29, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of XOMA in WallStreetBets Daily Discussion

XOMA News

Recent insights relating to XOMA

CNBC Recommendations

Recent picks made for XOMA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in XOMA

Corporate Flights

Flights by private jets registered to XOMA